Heußen F M, Ouyang Y, Joussen A M
Charité Universitätsmedizin Berlin, Klinik für Augenheilkunde, Berlin, Campus Virchow-Klinikum.
Klin Monbl Augenheilkd. 2012 Sep;229(9):877-81. doi: 10.1055/s-0032-1315084. Epub 2012 Aug 17.
Retinal angiomatous proliferations, also known as type 3 neovascularisation, are a common entity amongst patients with age-related macular degeneration. Their prevalence is being estimated at around 12-15% in this group of patients. Certain funduscopic signs like an extravofeal, intraretinal haemorrhage, cystoid macular oedema or a retinal anastomosis of the lesion are considered to be pathognomonic. Verification of the diagnosis should be based on ICG angiography, although OCT is gaining popularity. Interestingly, RAP lesions seem to have distinctive demographic characteristics and respond differently to established therapies, differentiating them from regular type 1 or type 2 neovascularisation. Current therapies of choice are VEGF inhibitors. Nonetheless, combination therapies, combining different approaches like anti-VEGF treatment and photodynamic therapy, have received more attention recently.
视网膜血管瘤样增殖,也称为3型新生血管形成,在年龄相关性黄斑变性患者中是一种常见情况。据估计,在这类患者中其患病率约为12% - 15%。某些眼底体征,如视网膜下、视网膜内出血、黄斑囊样水肿或病变的视网膜吻合,被认为具有诊断特异性。尽管光学相干断层扫描(OCT)越来越受欢迎,但诊断的确认仍应基于吲哚菁绿血管造影(ICG)。有趣的是,视网膜血管瘤样增殖(RAP)病变似乎具有独特的人口统计学特征,并且对既定治疗的反应不同,这使其有别于常见的1型或2型新生血管形成。目前的首选治疗方法是血管内皮生长因子(VEGF)抑制剂。尽管如此,联合治疗,即结合抗VEGF治疗和光动力疗法等不同方法,最近受到了更多关注。